12:51 PM
 | 
Mar 02, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DBV reports Phase I/II data for milk protein allergy therapy

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) reported preliminary data from the Phase II portion of the Phase I/II MILES trial to treat IgE-mediated cow’s milk protein allergy showing that the once-daily 300 µg dose of Viaskin Milk patch was identified as "most effective" tested dose for children.

The trial enrolled 198 patients ages 2-17 to receive placebo or once-daily 150, 300 or 500 µg Viaskin Milk. In...

Read the full 310 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >